Skip to content


  • Poster presentation
  • Open Access

Macrophage activation syndrome (MAS) in different pediatric rheumatic disease

  • 1,
  • 1, 2,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Pediatric Rheumatology201412 (Suppl 1) :P220

  • Published:


  • Systemic Lupus Erythematosus
  • Ferritin
  • Etoposide
  • Rheumatic Disease
  • Dermatomyositis


Macrophage activation syndrome (MAS) is a life-threatening complication of chronic rheumatic disease in childhood.


We aim to eveluate MAS findings and outcomes that differ according to disease in childhood.


We obtain 11 rheumatic patients followed in two different pediatric rheumatology units (Erciyes University and Ege University) who presented with MAS. We report their clinical and laboratory findings, therapies and outcomes.


The primary diagnoses of the patients included in the study, respectively; systemic juvenil idiopathic arthritis (n=5), Systemic Lupus Erythematosus (n=2), juvenile dermatomyositis (n=2), a neonatale onset multisystem inflammatory disease (NOMID) and a microscopic polyartritis nodosa. The mean age of the patients was 9.9 years old (1-14), and male to female ratio was 3:8. The mean duration of underlying disease was 6 months (1-24 months) at the diagnosis of MAS. We found MAS due to infection in four patients ,while used medicine in a patient. MAS were developed spontaneously in 6 patients. The clinical manifestations of MAS included fever 7 (63.6%),mucosal bleading 6 (54.5%), neurologic involvement 4 (36.4%) and hepatomegaly 6 (54.5%).

We found thrombocytopenia in 9 (81.8%), leucopenia in 5 (45.5 %), increased AST in 7 (63.6%), hypofibrinogenemia in 6 (54.5%), increased ferritin in 11 (100%), decreased ESH in 4 (36.4%) and increased triglyceride in 10 (90.9%) patients. We investigated bone marrow in all patients, and hemophagocytosis were determinated in 8 (72.7%). The medications were pulse methylprednisolone 6 (54.5%), intravenous immunoglobulin 8 (72.7%), plasma exchange 5 (45.5%), cyclosporine 6 (54.5%), dexamethasone 1 (9.1%), etoposide 1 (9.1%). The prognosis of patients were recovery 8 (72.7%), and exitus 3 (27.3%).


In conclusion, MAS can be developed in various pediatric rheumatologic disease and fatal. Prompt recognition and timely treatment can result good outcomes.

Disclosure of interest

None declared.

Authors’ Affiliations

Pediatric Rheumatology, Erciyes University, Kayseri, Turkey
Pediatric Rheumatology, Ege University, Izmir, Turkey


© Gunduz et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.